𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Alkylating agents induce activation of NFκB in multiple myeloma cells

✍ Scribed by Philipp Baumann; Sonja Mandl-Weber; Fuat Oduncu; Ralf Schmidmaier

Book ID
104040591
Publisher
Elsevier Science
Year
2008
Tongue
English
Weight
252 KB
Volume
32
Category
Article
ISSN
0145-2126

No coin nor oath required. For personal study only.

✦ Synopsis

Multiple myeloma is still not curable and drug combination strategies are currently being evaluated in order to achieve high remission rates with tolerable toxicity. Bortezomib has been shown to exert inhibitory effects on NFB activity. NFB in turn is known to be activated by cytokines, growth factors and by cellular adhesion to bone marrow stromal cells and represents an important mediator of primary and secondary drug resistance in multiple myeloma that confers to proliferation and survival.

In this study we confirm that bortezomib sensitized MM cells to the DNA-damaging drugs melphalan and doxorubicin. Further, we demonstrate that the sole incubation of MM cells with melphalan or doxorubicin leads to a vast activation of NFB activity. Additionally, we show that the co-incubation of bortezomib with melphalan or doxorubicin reduces activation of NFB. These data suggest that the drug-sensitizing effect of bortezomib on MM cells is due to inhibition of melphalan-and doxorubicin-induced activation of NFB activity.

This study, therefore, supports the idea of combining a NFB inhibitor with alkylating drugs in the therapy of multiple myeloma.

📜 SIMILAR VOLUMES

A novel NF-κB inhibitor DHMEQ selectivel
A novel NF-κB inhibitor DHMEQ selectively targets constitutive NF-κB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo
✍ Mariko Watanabe; Md. Zahidunnabi Dewan; Takamitu Okamura; Masataka Sasaki; Kinji 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 453 KB

Multiple myeloma (MM) is a fatal lymphoid malignancy that is incurable with conventional modalities of chemotherapy. Strong and constitutive activation of nuclear factor kappa B (NF-kappaB) is a common characteristic of MM cells. In our study we successfully target NF-kappaB with a novel NF-kappaB i